Thiophosphamide

Thiophosphamide is an antitumor cytostatic drug belonging to the imidazole group.

The drug contains the active substance thiophosphamide, a derivative of imidazolethiocarbamic acid. Prescribed for the treatment of solid malignant tumors:

* breast cancer (except receptor form); * solid tumors of the genitourinary system (with the exception of prostate cancer, non-metastatic bladder cancer and some other forms of tumors that are amenable to other treatment methods, such as radiotherapy); * chronic lymphocytic leukemia (CLL) and lymphomas (LML); * trophoblastic tumors; * malignant tumors of other localizations, recurrent and/or metastatic, refractory to other methods of chemotherapy or if they are intolerable.

The drug is used in monotherapy and combination treatment together with other cytostatics. Thiophosphanamide is contraindicated in patients who are highly sensitive to the drug. Not prescribed for pregnant patients and nursing mothers. Use with caution in patients with diseases of the lymphoid system, leukemia, diseases of red and white blood cells, and pathologies of the immune system. It is important to take into account the manifestation of side effects in such categories of citizens as children and elderly patients.

Thiophosphamide (thiopropane molecule) is an antitumor agent. Its main active ingredient was originally developed using a toxic poison. Being ondansetron, it is a prodrug which, because its molecules are quite large, is preferably obtained by extraction from plant materials by crystallization or isolated by other chemical methods. Chemical studies have shown that it is composed of thiophene, which has the same properties as protoporphyrin IX from which it was discovered.

The antitumor effect of thiophosphamide is associated with its ability to integrate into nucleic acids and influence their function. Mechanism of action of thiophos